Bronchoconstriction following nebulised colistin in cystic fibrosis

Arch Dis Child. 2001 May;84(5):432-3. doi: 10.1136/adc.84.5.432.


Nebulised colistin is regularly used as antipseudomonal therapy in children with cystic fibrosis. We assessed bronchoconstriction in response to nebulised colistin in 58 children. Nebulised colistin significantly reduced FEV(1), MEF(25%), and SaO(2) for 15 minutes. In 20 children the reduction was greater than 10% from baseline FEV(1), and was still at that level in five at 30 minutes. Subjective assessment, baseline FEV(1), and serum IgE were unable to identify susceptible children. It is recommended that children receiving colistin should be carefully assessed for bronchoconstriction.

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Bronchoconstriction / drug effects*
  • Child
  • Child, Preschool
  • Colistin / administration & dosage
  • Colistin / adverse effects*
  • Cross-Sectional Studies
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / physiopathology
  • Forced Expiratory Volume / drug effects
  • Humans
  • Prospective Studies


  • Anti-Bacterial Agents
  • Colistin